Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hygeia Healthcare Holdings Co., Limited 海吉亚医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6078)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONTINUING CONNECTED TRANSACTION THE PROCUREMENT AGREEMENTS WITH HANDAN RENHE HOSPITAL AND KAIYUAN JIEHUA HOSPITAL

Reference is made to the announcement of Hygeia Healthcare Holdings Co., Limited (the "Company", together with its subsidiaries as the "Group") dated September 14, 2021, in relation to the continuing connected transaction contemplated under the Procurement Agreements with each of Handan Renhe Hospital and Kaiyuan Jiehua Hospital, respectively (the "Announcement"). This announcement is supplemental to the Announcement and should be read in conjunction with the Announcement. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company would like to provide the following additional information in relation to (i) the Medicine and Medical Consumables and (ii) the pricing terms of the Procurement Agreements:

The Medicine to be supplied by Qihai Medicine to Handan Renhe Hospital and Kaiyuan Jiehua Hospital includes, but not limited to, the medicine for the treatment of breast cancer, ovarian cancer, gastric cancer, lung cancer, uremia and mental illness (such as Trastuzumab for Injection, Paclitaxel Injection, Recombinant Human Erythropoietin Injection (CHO Cell) and Olanzapine Tablets).

The Medical Consumables to be supplied by Jiangsu Supply Chain to Handan Renhe Hospital and Kaiyuan Jiehua Hospital include, but not limited to, general consumables (for example, medical gauze, syringes and cotton swabs) and high value medical consumables (for example, dialyzers and hemoperfusion devices).

The prices for the Medicine and Medical Consumables to be supplied by the Group under the Procurement Agreements are subject to the rules and regulations promulgated by local pricing authority(ies) and determined with reference to the government-prescribed prices set out in the relevant Medicine Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (基本醫療保險、工傷保險和生育保險藥品 目錄) and Medical Consumables Catalogue for Basic Medical Insurance (基本醫療保 險醫用耗材目錄) (the "Catalogues"). For the Medicine and Medical Consumables not covered in the Catalogues, the prices shall be determined based on normal commercial terms after arm's length negotiation between the parties taking into account: (i) the nature and specification of the Medicine and Medical Consumables; (ii) the market supply and demand situation; (iii) the procurement costs of the Medicine and Medical Consumables; (iv) the volume of the purchase order; (v) the respective market share of Oihai Medicine and Jiangsu Supply Chain; (vi) the comparative prices offered by independent third parties to the other hospitals within the same region if such comparative prices are made public; and (vii) any other factors affecting prices of the Medicine and Medical Consumables. Such prices shall be no more favorable than the prices of the same medicines and medical consumables offered by the Group to the other hospitals within the same region. Handan Renhe Hospital and Kaiyuan Jiehua Hospital are not obliged to purchase the Medicine and the Medical Consumables from the Group if the prices offered by the Group differ significantly from the prevailing government-prescribed prices in the Catalogues or market prices, as the case may be.

By order of the Board **Hygeia Healthcare Holdings Co., Limited Mr. Zhu Yiwen** *Chairman*

Hong Kong, September 28, 2021

As of the date of this announcement, the Board comprises Mr. Zhu Yiwen as chairman and executive Director, Mr. Fang Min as non-executive Director, Ms. Cheng Huanhuan, Mr. Ren Ai, Mr. Zhang Wenshan and Ms. Jiang Hui as executive Directors, and Mr. Liu Yanqun, Mr. Chen Penghui and Mr. Ye Changqing as independent non-executive Directors.